Invention Grant
US07807788B2 Chimeric and humanised monoclonal antibodies against Interleukin-13
有权
针对白细胞介素-13的嵌合和人源化单克隆抗体
- Patent Title: Chimeric and humanised monoclonal antibodies against Interleukin-13
- Patent Title (中): 针对白细胞介素-13的嵌合和人源化单克隆抗体
-
Application No.: US11570736Application Date: 2005-06-30
-
Publication No.: US07807788B2Publication Date: 2010-10-05
- Inventor: Claire Ashman , Martin John Cassidy , Jonathan Henry Ellis , Trevor Anthony Kenneth Wattam
- Applicant: Claire Ashman , Martin John Cassidy , Jonathan Henry Ellis , Trevor Anthony Kenneth Wattam
- Applicant Address: GB
- Assignee: Glaxo Group Limited
- Current Assignee: Glaxo Group Limited
- Current Assignee Address: GB
- Agent Jonathan M. Dermott; William T. Han
- Priority: GB0414799.7 20040701; GB0423675.8 20041025
- International Application: PCT/GB2005/002581 WO 20050630
- International Announcement: WO2006/003407 WO 20060112
- Main IPC: C07K16/00
- IPC: C07K16/00 ; C12P21/00
Abstract:
The present invention concerns immunoglobulins, particularly antibodies which specifically bind human Interleukin 13 (hIL-13). Antibodies of the invention may be used in the treatment of a variety of diseases or disorders responsive to modulation of the interaction between hIL-13 and the human IL-13 receptor. Such diseases include severe asthma, atopic dermatitis, COPD and various fibrotic diseases. Pharmaceutical compositions comprising said antibodies and methods of manufacture are also disclosed.
Public/Granted literature
- US20070258979A1 Chimeric and Humanised Monoclonal Antibodies Against Interleukin-13 Public/Granted day:2007-11-08
Information query
